 |
VasoMedical to Exhibit EECP® and BIOXTM Products at Medica 2013 |
Company to Introduce New MobiCareTM Wireless Monitor at the World’s Largest Medical Industry Show
WESTBURY, N.Y. – November 4, 2013 – VasoMedical, Inc. (“VasoMedical”) (OTCBB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology including Enhanced External Counterpulsation (EECP®) Therapy systems, the gold standard of ECP therapy, announced today that the Company will exhibit at the world's largest medical industry show – Medica 2013 – on November 20-23 in Dusseldorf, Germany.
Medica 2013 will take place this year at the Dusseldorf Fairgrounds and will bring together physicians, hospital administrators and department managers, nursing and patient care managers and staff, medical industry sales and marketing personnel, as well as other healthcare professionals from Europe and around the world. The 2012 show was attended by more than 130,000 members of the healthcare community and had more than 4,500 exhibitors showcasing the latest trends transforming the industry.
In addition to demonstrating its state-of-the-art EECP® technology, VasoMedical will also exhibit its BIOX ambulatory monitoring products. The Company will also use this opportunity to introduce its new BIOX MobiCareTM vital signs patient monitoring system to conference attendees. The MobiCareTM line of innovative patient monitoring systems eliminate the constraints of standard bedside monitoring by wirelessly transmitting patient vital signals including ECG, heart rate, respiration, SpO2, blood pressure and temperature, in real time to a bedside monitor or a tablet receiver, therefore providing optimal patient freedom and mobility. With its high quality, ease of use and attractive pricing, MobiCareTM patient monitors address the ever-increasing needs for medical devices in the emerging markets as they continue to grow as a result of expansion in economy and healthcare infrastructure, as well as the burgeoning needs in the home medical market in the developed countries to meet demand of managing chronic diseases of the aging population.
“Medica 2013 is the premier global event for those involved in the medical and healthcare marketplace. It presents VasoMedical with an ideal platform to showcase its products and present the value-added benefit of selecting VasoMedical as a partner of choice with its superior products. The timing of this event is also extremely important as we have begun to implement our plan to strengthen our presence internationally, introduce new products and expand our current product offering into new markets overseas,” said Larry Liebman, Vice President of Sales & Marketing at VasoMedical. “Being selected as an exhibitor at this year's Medica is a great step for VasoMedical, EECP® Therapy and our other products. The selection process is rigorous due to the number of companies vying for space and access to this extensive professional audience. We look forward to a great success in Medica and will continue to generate awareness, interest and excitement about our products and our Company.”
VasoMedical will be located in Hall 10 at booth G27.
About VasoMedical
VasoMedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company's main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, VasoMedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; VasoMedical Global operates the Company's China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company's website at www.vasomedical.com.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com
Media Contacts:
Samantha Wolf / Andrew Herweg
KCSA Strategic Communications
212-896-1220 / 212-896-1273
swolf@kcsa.com / aherweg@kcsa.com